Medicare Now Paying for EsoGuard; Q3 Revenue $1.2M, Record October Volume
LUCD sits 39% above its 52-week low of $0.303 on light trading volume (0.3× avg).
Summary
Lucid confirmed Medicare is now paying claims for EsoGuard at the established $1,938.01 per-test rate, the first real revenue channel for the test and the follow-through on the reimbursement milestones disclosed in September and the Reuters report in late October. Q3 revenue was $1.2 million on 2,871 tests, essentially flat versus $1.2 million a year ago and short of analyst expectations, while operating expenses rose to $13.5 million, the GAAP net loss was $6.7 million, or $(0.03) per share, and the EBITDA loss was $6.5 million. October test volume topped 1,800, a record month, which management frames as the start of commercial acceleration now that Medicare coverage is no longer the constraint. Cash stood at $18.0 million at quarter end, before the $15.0 million Series C preferred financing closed in October — a modest runway against roughly $13.5 million of quarterly opex, and the stock remains under Nasdaq's $1.00 bid-price notice from October 12. The pending MolDX LCD reconsideration is the swing factor; management says the delay is administrative backlog and expects a draft LCD as it clears. PAVmed (PAVM) is the parent and holds the Lucid stake, so it is affected indirectly through valuation marks rather than operations.
At the time of this announcement, LUCD was trading at $0.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $77.5M. The 52-week trading range was $0.30 to $1.63. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: PR Newswire.